Dyne Therapeutics Inc
NASDAQ:DYN

Watchlist Manager
Dyne Therapeutics Inc Logo
Dyne Therapeutics Inc
NASDAQ:DYN
Watchlist
Price: 18.5 USD -5.42% Market Closed
Market Cap: 2.6B USD

Relative Value

There is not enough data to reliably calculate the relative value of DYN.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DYN Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-4.5
Industry
23.5
Forward
-5.1
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-5
Industry
21.9
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-5.2
Industry
24.3
vs History
26
vs Industry
39
Median 3Y
3.5
Median 5Y
2.6
Industry
3.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10.1
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.4
Industry
5.9
Forward
-4.4
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-2.7
Industry
6.2
Forward
-4.1
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-3.1
Industry
7.7
vs History
vs Industry
Median 3Y
-3.2
Median 5Y
-3
Industry
6.3
vs History
36
vs Industry
13
Median 3Y
18.7
Median 5Y
17.7
Industry
5.6

Multiples Across Competitors

DYN Competitors Multiples
Dyne Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Dyne Therapeutics Inc
NASDAQ:DYN
2.6B USD 0 -6.2 -4.4 -4.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 837 682.7 -160 825.5 -195 293.4 -193 064.9
US
Abbvie Inc
NYSE:ABBV
405.3B USD 6.8 172.6 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
176.3B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
151B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 082 -531.3 -578.5 -563.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD 5.7 17.9 17 19.3
AU
CSL Ltd
ASX:CSL
83.5B AUD 3.6 18.6 12.6 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.6 163.2 198
NL
argenx SE
XBRU:ARGX
43.5B EUR 14.1 33.1 57.3 58.9
P/S Multiple
Revenue Growth P/S to Growth
US
Dyne Therapeutics Inc
NASDAQ:DYN
Average P/S: 3 383 983.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 837 682.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 082
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
14.1
49%
0.3
P/E Multiple
Earnings Growth PEG
US
Dyne Therapeutics Inc
NASDAQ:DYN
Average P/E: 191
Negative Multiple: -6.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 825.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.6
N/A N/A
NL
argenx SE
XBRU:ARGX
33.1
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Dyne Therapeutics Inc
NASDAQ:DYN
Average EV/EBITDA: 40.1
Negative Multiple: -4.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 293.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.2
N/A N/A
NL
argenx SE
XBRU:ARGX
57.3
810%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Dyne Therapeutics Inc
NASDAQ:DYN
Average EV/EBIT: 46.3
Negative Multiple: -4.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 064.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198
N/A N/A
NL
argenx SE
XBRU:ARGX
58.9
N/A N/A